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New Approaches to Diabetes Disease Control,
Insulin Delivery, and Monitoring
In the United States, 18.2 million t
people have the endocrine disease s
diabetes, but as many as one-third e
do not even know it. About 5%– i
10% have type 1 diabetes, whereby a
the body fails to make sufficient in- t
sulin and the person requires exog- f
enous insulin supplementation. Most v
Americans who are diagnosed with c
the disease have type 2 diabetes, a
which usually develops later in life. c
This type of diabetes is often suc- L
cessfully managed through lifestyle t
modifications and possibly non-insu- t
lin medications, although some peo-
ple with type 2 diabetes require in-
sulin support.
ABecause diabetes is a medical
condition without any cure at this b
point—and its incidence is on the d
rise—researchers are actively seek-
1ing advances targeting the source
or triggers of the disease, delivery U
of therapeutics, and tighter man- pagement of its long-term complica-
stions.
lAnti-CD3 Antibodies May Delay
Disease Progression hResearchers in the United States
and Europe are enthusiastically pur-
suing therapies designed to halt or
tslow the progression of type 1 dia-
fbetes, even if it may not yet be pos-
tsible to stop it from developing in
tthe first place. Type 1 diabetes mel-
ilitus is a chronic autoimmune dis-
wease that results when T lymphocytes
ccause the destruction of insulin-pro-
aducing beta cells inside pancreatic
tislet cells. One such therapy involves
Htreatment with anti-CD3 monoclo-
tnal antibodies (Mabs), the focus of
Awhich is two-fold: to directly inhibit
bthe action of destructive T cells and
csimultaneously induce the action of
vprotective T regulatory cells. Re-
fsearchers involved in anti-CD3 anti-
nbody research believe the antibody
sreestablishes a balance between pa-
cthogenic and regulatory T cells such
sthat diabetes disease progression
Imay be significantly slowed.
tThe original anti-CD3 monoclonal
hantibody, known as OKT3, was de-
wrived from murine sources and hasbeen used extensively in transplan-ation medicine. In 1994, when re- t
iearch into anti-CD3 Mabs began in
iarnest in animal studies, a human-
czed version was not available. “The
1ntibodies used then in clinic for
pransplantation induced side ef-
aects because they can also acti-
aate T cells, which in turn induces
tytokine release,” says long-term
cnti-CD3 antibody researcher Lu-
rienne Chatenoud, M.D., from the
saboratoire d'Immunologie at Hôpi-
aal Necker in Paris. “When these an-




lthough it may not yet q
ge possible to prevent
tiabetes—which affects
t
8.2 million people in the w
Cnited States—in the first
Place, researchers are pur- Y
uing several promising b
beads on ways to slow or
dalt the disease. l
a
w
ransplant patients, they induced the h
lu-like syndrome. This was some- n
hing affordable in the transplant set-
ing because [transplant rejection]
I
s a life-threatening situation, but it
O
a
as not the kind of side effect that a
ould be afforded in the context of w
disease like type 1 diabetes, where b
here is an alternative treatment.” s
umanized anti-CD3 monoclonal an- n
ibodies, such as hOKT3gamma1(Ala- b
la), are mouse-human hybrid anti- c
odies that selectively bind to beta- A
ell-specific T phocytes. Humanized d
ersions do not activate harmful in- 1
lammatory cytokines that cause M
ausea, fever, headache, hyperten- a
ion, and even cardiac problems, t
ommonly seen in the transplant a
etting with murine-based versions. u
n May 2002, researchers published c
he first human clinical studies of t
OKT3gamma1(Ala-Ala) in people d
ho had been diagnosed within 6 Sweeks with type 1 diabetes. Althoughhe study was small—24 volunteers
n total—the results are encourag-
ng. After only a single 14 day
ourse of antibody treatment, 9 of
2 patients had maintained or im-
roved insulin production as far out
s one year. Responses were seen
s soon as 30 to 90 days after
reatment. In contrast, only 2 of 12
ontrol volunteers had a sustained
esponse. Very recently, the re-
earchers followed the subjects for
nother year—without retreatment—
nd found a sustained effect. “It
oes not permanently prevent dia-
etes from progressing, but it at
east seems to stabilize things for
uite a while. It kept them from pro-
ressing with just 10–14 days of
reatment,” says lead scientist for
his study, Kevan C. Herold, M.D.,
ho is an associate professor at
olumbia University College of
hysicians and Surgeons in New
ork. Herold found that the anti-
ody reduces glycosylated hemoglo-
in levels as well as necessary insulin
oses. Non-severe side effects were
imited mainly to fever, rash, and
nemia. Drs. Chatenoud and Herold
ill publish results of other phase II
uman studies with anti-CD3 mo-
oclonal antibodies in 2005.
nhaled Insulin Delivery
nce type 1 diabetes (or occasion-
lly type 2) progresses to the point
t which insulin is required, treatment
ith one of a number of needle-
ased injection devices is fairly
tandard. However, several compa-
ies are pursuing insulin systems
ased on inhaled delivery. One such
ompany, Hayward, California-based
radigm Corporation, partnered with
iabetes care giant Novo-Nordisk in
998 to develop the AERx Diabetes
anagement System (AERx iDMS),
n aerosolized inhaled insulin sys-
em. “The foundation of Aradigm,
nd AERx iDMS in particular, is to
se microprocessors within a medi-
al device to enable precisely con-
rolled delivery of an aerosolized
rug from that device,” explains
teven Farr, Ph.D., Chief ScientificOfficer at Aradigm. “The company
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1598was founded on the theory of using l
the lung as a portal of entry for d
drugs that are currently given by in- h
jection, of which insulin is a great M
example.” C
Dr. Farr explains that the greatest
difference between AERx iDMS and
S
c
other inhaled insulin systems in de- a
velopment is that Aradigm has de- p
veloped a liquid formulation of insu- a
lin that becomes aerosolized into t
the lungs of patients when they in- k
hale it. “All of the other players are r
developing dry powders of insulin,” t
says Dr. Farr. “We selected an k
aqueous system because insulin t
has been in a liquid formulation in a
excess of 70 years. We leveraged o
all that was known about an inject- p
able form of insulin to create a spe- a
cific formulation incorporated into s
our device for inhalation. The excip- t
ients we use to stabilize the insulin t
in our aerosolized formulation are e
the same as those in the injectable B
formulations. Our testing to date c
shows this approach to be safe.” m
The AERx iDMS system, currently t
in phase III clinical testing with part- n
ner Novo-Nordisk, was designed to w
offer the major conveniences and b
requirements of today’s pen injec- o
tors. “This device allows patients to t
adjust their doses with the same o
degree of accuracy and precision r
they demand from pen injection c
systems,” says Dr. Farr. To create d
the aerosol in the AERx device, a t
small aliquot of liquid insulin, ac- t
cording to the required dose, y
passes through a plastic film manu- d
factured with 1 m-size holes. “That a
was a significant technological chal- t
lenge we had to resolve in order to
ensure we had the right-sized aerosol t
particles for deep lung delivery,” re- d
calls Dr. Farr. t
Other inhaled insulin products— l
though all based on dry-powder in- p
sulins—are in the development pipe- a
line. These include the Exubera pro- f
duct, which Pfizer, Aventis, and n
Nektar Therapeutics now have in b
phase III testing and for which they p
are awaiting European market ap- s
proval. Eli Lilly, another major player c
in the diabetes market, has joined i
ranks with drug delivery manufac- t
turer Alkermes to produce the in- b
haled AIR delivery system. The pro- A
duct is now in phase II testing for i
fdiabetes. Additionally, Mannkind
Corporation just completed phase II m
testing with its Technosphere Insu- lin System, although no commercial
evelopment or marketing partner
as yet been identified.
onitoring for Kidney
omplications
ome of the most dangerous out-
omes of either form of diabetes
re those related to long-term com-
lications, including kidney dam-
ge, or diabetic nephropathy. Over
ime, small blood vessels inside the
idneys can become damaged and
educe the body’s ability to filter
oxins from the blood. Damaged
idneys leak a protein, albumin, into
he urine. Detection of even small
lbumin levels, microalbuminuria, is
ne of the earliest signs of kidney
roblems, and also one that is not
lways noticeable in the earliest
tages of the disease. Left un-
reated, the damage worsens until
he kidneys fail, a condition called
nd-stage renal disease (ESRD).
ecause of the serious long-term
onsequences of kidney damage, in
id-November, 2004 the Interna-
ional Society of Nephrology urged
ational health bodies around the
orld to proactively implement al-
uminuria screening with the goal
f preventing further kidney func-
ion deterioration in diabetics and
thers with kidney disease. Cur-
ently, the American Diabetes Asso-
iation recommends that people
iagnosed with type 2 diabetes be
ested for microalbuminuria at the
ime they are diagnosed and every
ear thereafter. Those with type 1
iabetes should be tested 5 years
fter diagnosis and every year
hereafter.
New York, NY-based AusAm Bio-
echnologies, founded in 2000, has
eveloped a new type of diagnostic
est to better detect extremely low
evels of albuminuria. The FDA ap-
roved the company’s Accumin di-
gnostic test in August 2003 as the
irst test to measure total intact uri-
ary albumin. The technology is
ased on the work of Wayne Com-
er, Ph.D., D.Sc., of Monash Univer-
ity, Australia. “The problem with
onventional tests for urine albumin
s that they can miss intact albumin
hat does not react with the anti-
odies used in making these tests.
s a result, conventional urine test-
ng is subject to a potentially large
alse negative rate for microalbu-
inuria,” says Mr. James McCul-
ough, AusAm’s CEO. “It was de-rived from raising antibodies to
serum albumin. Dr. Comper recog-
nized that as the serum albumin
passes through the kidney and out
through the urine, it can undergo a
slight conformational change ren-
dering it unreactive to conventional
serum-derived albumin antibodies.
In other words, intact albumin that
is invisible to conventional antibod-
ies—which is in all the major manu-
facturers’ platforms and dipsticks—
ends up unrecognized in the urine.”
In the clinical tests that Dr. Comper
and colleagues performed, conven-
tional tests generated a 33% false
negative rate for microalbuminuria
when they were compared with Ac-
cumin.
“In May 2004, we published that we
can detect microalbuminuria up to 12
years earlier than radioimmunoas-
say, which is the most sensitive of
the conventional urine tests,” says
McCullough, “But on average, it is
really about 3 years earlier.” The key,
claims McCullough, is that the anti-
body used in the test was raised to
urine albumin. “After doing 2D elec-
trophoresis and HPLC, we discovered
this whole population of intact albu-
min which was unrecognizable by the
conventional antibodies in all the ma-
jor immunoassays around the world,”
says McCullough.
The test is done in combination
with a test for creatinine, a protein
excreted by the muscles. The results
are reported as a ratio of microalbu-
min/creatinine. “If you are above 30
mg of albumin per gram of creatinine,
you are said to be microalbuminuria
positive,” explains McCullough. “We
can pick up as low as 3–4 mg albu-
min per gram of creatinine.”
“We are platform agnostic,” says
McCullough. “The FDA-approved
Accumin quantitative test is cur-
rently done with chromatography.
But we are in the process now of
working with several analyzer com-
panies to place the technology in
high-throughput immunochemical
devices.” In 2005, AusAm hopes to
roll out a dipstick version of the
technology to bring it even closer to
the point of care.
Chemistry & Biology invites your
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